September 13, 2013 (Shareholders Foundation) - An investigation on behalf of investors of OvaScience Inc (NASDAQ:OVAS) shares over potential securities laws violations by OvaScience and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of OvaScience Inc (NASDAQ:OVAS) concerning whether a series of statements OvaScience regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 11, 2013, OvaScience Inc provided a regulatory, manufacturing and international strategy update on AUGMENT, the Companys product candidate designed to improve egg quality and increase the success of in vitro fertilization.

OvaScience Inc said it has chosen to suspend enrollment of AUGMENT in the U.S. while moving forward with its plans for enrollment outside of the U.S.
Furthermore, OvaScience Inc said that on September 6, 2013, it received an untitled letter from the Food and Drug Administration (FDA) questioning the status of AUGMENT as a 361 HCT/P and advising the Company to file an Investigational New Drug (IND) application.

OvaScience Inc (NASDAQ:OVAS) declined from $14.29 per share on September 10, 2013, to $9.124 per share on September 11, 2013.